Clinical Trial Search

Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants

Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle — 77.0 percentage of participants

Primary: Time to Clinical Stability (Kaplan-Meier Estimate) — 23.7; 37.0; 28.1 hours — p=0.306

Primary: The Comparison of Functional Immune Reconstitution at 6-9 Months Following Transplant as Measured by Antibody Response to Vaccination With Inactivated Hepatitis A or B…

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 37; 33; 34; 31 Participants

Primary: Time to Alleviation of Symptoms (Kaplan-Meier Estimate) — 136.2; 114.1; 117.4 Hours — p=0.377

Primary: Acute Stress Measured by Tension — 3089.4; 3253.4 mm*min — p=0.1233

Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 92.3 percentage of participants

Primary: Percentage of Participants Who Died Assessed From Point of Randomization — 81.3; 85.7 percentage of participants

Primary: Acute Stress Measured by Tension — 3335.7; 3360.3 mm*min — p=0.7726

Primary: Number of Patients That Achieved a Complete Response or a Partial Response (PR) — 32 participants

Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores — -12.46; -13.35; -18.02; -4.18 scores on a scale

Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) Antibodies. — 27; 10; 9; 8 subjects

Primary: Rate of T Stage Downstaging — 71 percentage of participants

Primary: HIV Viral Load < 400 Copies/ml — 40; 50 percentage of participants